PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17076650-3	2006	Lenalidomide (CC-5013; Revlimid), a second generation IMiD, has shown significant erythropoietic activity in patients with lower risk MDS that have failed or are not candidates for recombinant erythropoietin treatment.	Lenalidomide	0-12	erythropoietin	Homo sapiens	193-207	
17076650-3	2006	Lenalidomide (CC-5013; Revlimid), a second generation IMiD, has shown significant erythropoietic activity in patients with lower risk MDS that have failed or are not candidates for recombinant erythropoietin treatment.	Lenalidomide	14-21	erythropoietin	Homo sapiens	193-207	
17076650-3	2006	Lenalidomide (CC-5013; Revlimid), a second generation IMiD, has shown significant erythropoietic activity in patients with lower risk MDS that have failed or are not candidates for recombinant erythropoietin treatment.	Lenalidomide	23-31	erythropoietin	Homo sapiens	193-207	
17076650-4	2006	Unlike cytokine therapy, lenalidomide suppresses select MDS clones and enhances erythropoietin receptor signaling to restore erythropoiesis.	Lenalidomide	25-37	erythropoietin	Homo sapiens	80-94	
17076650-10	2006	A phase III Intergroup trial (ECOG 2905) will test the capacity to potentiate erythropoietin response by comparing response to lenalidomide monotherapy to the combination of darbepoetin and lenalidomide in non-deletion 5q MDS patients.	Lenalidomide	127-139	erythropoietin	Homo sapiens	78-92	
17076650-10	2006	A phase III Intergroup trial (ECOG 2905) will test the capacity to potentiate erythropoietin response by comparing response to lenalidomide monotherapy to the combination of darbepoetin and lenalidomide in non-deletion 5q MDS patients.	Lenalidomide	190-202	erythropoietin	Homo sapiens	78-92